Leap Investments’s SELLAS Life Sciences SLS Stock Holding History

Leap Investments’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,823	Closed	-$47K	–	544
2019 Q4	$47K	Buy	+10,823	New	+$58.3K	0.02%	400

Other funds holding SLS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Leap Investments's SLS Position: Q1 2020 in Review

Leap Investments sold out of SELLAS Life Sciences (SLS) in Q1 2020, closing a stake of 10,823 shares — an estimated $47K sold.

Leap Investments first reported a position in SLS in Q4 2019 and held it in 1 quarter. The position peaked at $47K in Q4 2019. 15 funds tracked by Wall St. Rank hold SLS as of Q1 2020.

Leap Investments reported no remaining SELLAS Life Sciences position as of Q1 2020 after selling out during the quarter.
Leap Investments sold 10,823 SELLAS Life Sciences shares in Q1 2020, an estimated $47K.
Leap Investments first reported a position in SELLAS Life Sciences in Q4 2019 and held it in 1 quarter.
Leap Investments's SELLAS Life Sciences position peaked at $47K in Q4 2019.
15 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2020.

Based on Leap Investments's 13F filing for Q1 2020, filed 15 May 2020.